The top pathways were as below: PPAR signaling pathway (Ppard, Fabp4, Scd1, Slc27a1, Cpt1a, Acsl1, Acadm), Adipocytokine signaling pathway (Prkaa1, Adipor1, Tnf, Nfkb1, Slc2a4, Cpt1a, Acsl1), AMPK signaling pathway (Prkaa1, Hmgcr, Adipor1, Acaca, Scd1, Cpt1a, Slc2a4), Non-alcoholic fatty liver disease (NAFLD) (Prkaa1, Adipor1, Tnf, nfkb1, Cebpa, Map3k5, Fas), Fatty acid metabolism (Acaca, Scd1, Cpt1a, Acsl1, Acadm), MAPK signaling pathway (Tnf, Nfkb1, Map3k5, Fas, Ntrk2), TNF signaling pathway (Tnf, Nfkb1, Map3k5, Fas), Insulin signaling pathway (Prkaa1, Acaca, Slc2a4, Ptbn1). This evidence concerns the gene CEBPA and metabolic dysfunction-associated steatotic liver disease.